Video Shorts

0:59
Follow-Up After Focal Cryo-Ablation in Intermediate Favorable Risk Prostate Cancer
23 days ago
by
Herbert Lepor, MD

1:10
Highlighting the Role of Real-World Studies in Bladder Cancer
23 days ago
by
Mark D. Tyson, II, MD, MPH

0:36
Implementing a Multidisciplinary Quality Initiative in Prostate Cancer
24 days ago
by
Jason Hafron, MD

0:30
Real-World Experience With BCG Retreatment After BCG Failure in NMIBC
24 days ago
by
Joshua J. Meeks, MD, PhD

0:51
Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Prostate Cancer
25 days ago
by
Mark Garzotto, MD

0:38
Examining the Landscape of Biomarkers in RCC
25 days ago
by
Benjamin Croll, MD

1:57
Sequencing T-Cell–Redirecting Therapies in Multiple Myeloma
25 days ago
by
Diana Cirstea, MD

0:27
Breaking Down the FDA Approval of Nivolumab AVD for Untreated Classical Hodgkin Lymphoma
25 days ago
by
Alex Herrera, MD

1:09
Unpacking the Design of the NCCN Advocacy Academy
a month ago
by
Alyssa Schatz, DrPH, MSW

1:30
Pan-RAS Inhibition Opens New Therapeutic Frontiers in Pancreatic Cancer
a month ago
by
Tanios S. Bekaii-Saab, MD

0:46
Outlining the Importance of Updated WHO Diagnostic Criteria for AML
a month ago
by
Sanam Loghavi, MD

0:52
Understanding Why the FDA Approval of Sonrotoclax for MCL is Important
a month ago
by
Tycel Phillips, MD

1:20
AI-Powered Imaging May Change Early Pancreatic Cancer Detection
a month ago
by
Tanios S. Bekaii-Saab, MD

1:50
Expert Insights on FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
a month ago
by
Courtney DiNardo, MD, MSCE(+1 more)

0:42
The Implications of the SATEEN Trial in HER2+ Metastatic Breast Cancer
a month ago
by
Kelly E. McCann, MD, PhD

1:26
Tracking the Evolution of Radiopharmaceuticals in Prostate Cancer
a month ago
by
Jeff Michalski, MD, MBA, FASTRO

1:47
Managing Mogamulizumab-Associated Rash in CTCL
a month ago
by
Brad Haverkos, MD

1:35
Highlighting the Advantages of Proton Therapy
a month ago
by
Madhur Garg, MD, MBA, FACR

1:12
Contextualizing the VIKTORIA-1 Trial in Breast Cancer Prior to ASCO 2026
a month ago
by
VK Gadi, MD, PhD

1:06
Treatment and Clinical Trial Considerations in Myeloma Subgroups
a month ago
by
Rebecca Silbermann, MD, MMS

4:12
OncLive News Roundup for the Week of 5/3
a month ago
by
Chris Ryan(+1 more)

1:16
Highlighting the Importance of Raising Bladder Cancer Awareness
a month ago
by
Matthew D. Galsky, MD

1:09
Evolving Management of p53-Mutated Mantle Cell Lymphoma
a month ago
by
Tycel Phillips, MD

0:55
MANEUVER Trial Supports Integration of Targeted Therapy Into Upfront TGCT Management
a month ago
by
R. Lor Randall, MD, FACS

1:45
Discussing the Implications of the SERENA-6 Trial Design
a month ago
by
Alexis LeVee, MD

0:54
Addressing Challenges With Anemia Management in Myelofibrosis
a month ago
by
Anthony M Hunter, MD

0:52
Breaking Down the Current State of CAR T-Cell Therapies in PCNSL
a month ago
by
Ashley Sumrall, MD

0:50
MountainTAP-30 Trial Seeks to Leverage PRMT5 Inhibitor for MTAP-Deleted Pancreatic Cancer
a month ago
by
Shubham Pant, MD, MBBS

1:34
Frontline Treatment and Transplant Considerations in Multiple Myeloma
a month ago
by
Ajai Chari, MD

2:13
The Pathologist's Role in Breast Cancer Biomarker Testing
a month ago
by
Dara S. Ross, MD
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5
